210 related articles for article (PubMed ID: 23079060)
21. Eltrombopag for the treatment of aplastic anemia: current perspectives.
Lum SH; Grainger JD
Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288
[TBL] [Abstract][Full Text] [Related]
22. [Successful immunosuppressive therapy for a patient with hypoplastic myelodysplastic syndrome].
Takanashi M; Kadono Y; Tabata Y; Hibi S
Rinsho Ketsueki; 1999 Oct; 40(10):1093-9. PubMed ID: 10565227
[TBL] [Abstract][Full Text] [Related]
23. Recent developments in drug therapy for aplastic anemia.
Willis L; Rexwinkle A; Bryan J; Kadia TM
Ann Pharmacother; 2014 Nov; 48(11):1469-78. PubMed ID: 25184310
[TBL] [Abstract][Full Text] [Related]
24. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
Passweg JR; Giagounidis AA; Simcock M; Aul C; Dobbelstein C; Stadler M; Ossenkoppele G; Hofmann WK; Schilling K; Tichelli A; Ganser A
J Clin Oncol; 2011 Jan; 29(3):303-9. PubMed ID: 21149672
[TBL] [Abstract][Full Text] [Related]
25. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
Stadler M; Germing U; Kliche KO; Josten KM; Kuse R; Hofmann WK; Schrezenmeier H; Novotny J; Anders O; Eimermacher H; Verbeek W; Kreipe HH; Heimpel H; Aul C; Ganser A
Leukemia; 2004 Mar; 18(3):460-5. PubMed ID: 14712285
[TBL] [Abstract][Full Text] [Related]
26. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.
Saunthararajah Y; Nakamura R; Nam JM; Robyn J; Loberiza F; Maciejewski JP; Simonis T; Molldrem J; Young NS; Barrett AJ
Blood; 2002 Sep; 100(5):1570-4. PubMed ID: 12176872
[TBL] [Abstract][Full Text] [Related]
27. [Combination of rabbit antithymocyte globulin and cyclosporine A as first-line therapy for adult severe aplastic anemia].
Cao HM; Wang HJ; Zhang L; Jing LP; Zhou K; Yang DL; Li HQ; Liu QG; Yan ZS; Liu YZ; Wu YH; Chu YL; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):38-42. PubMed ID: 21429400
[TBL] [Abstract][Full Text] [Related]
28. Antithymocyte globulin and cyclosporine in children with aplastic anemia: a developing country experience.
Sharma R; Chandra J; Sharma S; Pemde H; Singh V
J Pediatr Hematol Oncol; 2012 Mar; 34(2):93-5. PubMed ID: 22278201
[TBL] [Abstract][Full Text] [Related]
29. Effects and Predictive Factors of Immunosuppressive Therapy Combined with Umbilical Cord Blood Infusion in Patients with Severe Aplastic Anemia.
Zhang X; Li Z; Geng W; Song B; Wan C
Yonsei Med J; 2018 Jul; 59(5):643-651. PubMed ID: 29869462
[TBL] [Abstract][Full Text] [Related]
30. Novel therapeutic choices in immune aplastic anemia.
Scheinberg P
F1000Res; 2020; 9():. PubMed ID: 32953089
[TBL] [Abstract][Full Text] [Related]
31. [Outcome of immunosuppressive therapy for myelodysplastic syndromes: results of 12 cases from a single institution].
Miyata A; Yasuda Y; Fujii S; Kikuchi T
Rinsho Ketsueki; 2002 Oct; 43(10):911-7. PubMed ID: 12462026
[TBL] [Abstract][Full Text] [Related]
32. Recent Advances and Long-Term Results of Medical Treatment of Acquired Aplastic Anemia: Are Patients Cured?
Scheinberg P
Hematol Oncol Clin North Am; 2018 Aug; 32(4):609-618. PubMed ID: 30047414
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation.
Kojima S; Horibe K; Inaba J; Yoshimi A; Takahashi Y; Kudo K; Kato K; Matsuyama T
Br J Haematol; 2000 Oct; 111(1):321-8. PubMed ID: 11091219
[TBL] [Abstract][Full Text] [Related]
34. [Polyclonal rabbit antithymocyte globulin (thymoglobulin): immunomodulatory effects and new aspects of its clinical application].
Kulagin AD; Lisukov IA; Miloserdov IA; Afanas'ev BV
Ter Arkh; 2010; 82(7):65-72. PubMed ID: 20853613
[TBL] [Abstract][Full Text] [Related]
35. Survival after immunosuppressive therapy in children with aplastic anemia.
Nair V; Sondhi V; Sharma A; Das S; Sharma S
Indian Pediatr; 2012 May; 49(5):371-6. PubMed ID: 22080620
[TBL] [Abstract][Full Text] [Related]
36. Antibodies in the treatment of aplastic anemia.
Gómez-Almaguer D; Jaime-Pérez JC; Ruiz-Arguelles GJ
Arch Immunol Ther Exp (Warsz); 2012 Apr; 60(2):99-106. PubMed ID: 22307362
[TBL] [Abstract][Full Text] [Related]
37. Rabbit antithymocyte globulin treatment in childhood acquired severe aplastic anemia.
Karapinar DY; Karadaş N; Ay Y; Akin M; Balkan C; Aydinok Y; Kavakli K
Pediatr Hematol Oncol; 2014 Feb; 31(1):20-8. PubMed ID: 23627541
[TBL] [Abstract][Full Text] [Related]
38. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.
Saunthararajah Y; Nakamura R; Wesley R; Wang QJ; Barrett AJ
Blood; 2003 Oct; 102(8):3025-7. PubMed ID: 12829603
[TBL] [Abstract][Full Text] [Related]
39. [Antithymocyte/Antilymphocyte globulin plus cyclosporine A therapy for the treatment of older patients with severe aplastic anemia].
Li JP; Yang WR; Li Y; Ye L; Zhou K; Jing LP; Li Y; Peng GX; Song L; Zhang FK; Zhang L
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):607-10. PubMed ID: 27535863
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.
Sloand EM; Barrett AJ
Hematol Oncol Clin North Am; 2010 Apr; 24(2):331-41. PubMed ID: 20359629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
